Evaluation and management of fungal infections in immunocompromised patients

Dermatologic Therapy

Volumn 18, Issue 1, 2005, Pages 44-57

  Venkatesan, Priya ^a   Perfect, John R ^b   Myers, Sarah A ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fungal infection; Immunosuppressed; Treatment

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYALOHYPHOMYCOSIS; IMMUNE DEFICIENCY; MALASSEZIA; MUCORMYCOSIS; MYCOSIS; ORGAN TRANSPLANTATION; PENICILLINOSIS; PHAEOHYPHOMYCOSIS; PREVALENCE; REVIEW; SPOROTRICHOSIS; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; DERMATOMYCOSES; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; ORGAN TRANSPLANTATION;

EID: 18844392815     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.05001.x     Document Type: Review

References (64)

1. CDC. HIV/AIDS surveillance report. Atlanta, GA: US Department of Health and Human Services, CDC, 2004. Avail.
2. Rinaldi MG. Dermatophytosis: epidemiological and microbiological update. J Am Acad Dermatol 2000: 43 (5 Suppl. 1): S120-S124.
3. Sentamil SG, Kamalam A, Ajithados K, Janaki C, Thambiah AS. Clinical and mycological features of dermatophytosis in renal transplant recipients. Mycoses 1999: 42: 75-78.
4. Johnson RA. Dermatophyte infections in human immune deficiency virus (HIV) disease. J Am Acad Dermatol 2000: 43 (5 Suppl.): S135-S142.
5. Smith KJ, Skelton HG, Yaeger J et al. Cutaneous findings in HIV-1 positive patients: a 42-month prospective study. J Am Acad Dermatol 1994: 31: 746-754.
6. Garman ME, Tyring SK. The cutaneous manifestations of HIV infection. Dermato/Clin 2002: 20: 193-208.
7. Tsang P, Hopkins T, Jimenez-Lucho V. Deep dermatophytosis caused by Trichophyton rubrum in a patient with AIDS. J Am Acad Dermatol 1996: 34: 1090-1091.
8. Nir-Paz R, Elinav H, Pierard GE et al. Deep infection by Trichophyton rubrum in an immunocompromised patient. J Clin Microbiol 2003: 41: 5298-5301.
9. Squeo RF, Beer R, Silvers D, Weitzman I, Grossman M. Invasive Trichophyton rubrum resembling blastomycosis infection in the immunocompromised host. J Am Acad Dermatol 1998: 39: 379-380.
10. Sequeira M, Burdick AE, Elgart GW, Berman B. New-onset Majocchi's granuloma in two kidney transplant recipients under tacrolimus treatment. J Am Acad Dermatol 1998: 38: 486-488.
11. Rhie S, Turcios R, Buckley H, Suh B. Clinical features and treatment of Malassezia folliculitis with fluconazole in orthotopic heart transplant recipients. J Heart Lung Transplant 2000: 19: 215-219.
12. Fichtenbaum CJ, Powderly WG. Recurrent oral candidiasis in HIV-infected patients. Infect Med 1994: 11: 191-200.
13. Wright SW, Johnson RA. Human immunodeficiency virus in women: mucocutaneous manifestations. Clin Dermatol 1997: 15: 93-111.
14. Conant MA. Fungal infections in immunocompromised individuals. Dermatol Clin 1996: 14: 155-162.
15. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment. Drugs 2004: 64: 1163-1180.
16. Singh N. Antifungal prophylaxis in organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000: 31: 545-553.
17. Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003: 75: 2023-2029.
18. Radentz WH. Opportunistic fungal infections in immunocompromised hosts. J Am Acad Dermatol 1989: 20: 989-1003.
19. Walsh TJ. Primary cutaneous aspergillosis - an emerging infection among immunocompromised patients. Clin Infect Dis 1998: 27: 453-457.
20. Pia MP, Berenguer J, Arzuaga JA et al. Surgical wound infection by Aspergillus fumigatus in liver transplant recipients. Diagn Microbiol Infect Dis 1992: 15: 703-706.
21. Van Burik JH, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998: 36: 3115-3121.
22. Roilides E, Fannaki E. Human immunodeficiency virus infection and cutaneous aspergillosis. Arch Dermatol 2000: 136: 412-414.
23. Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ. Invasive aspergillosis in HIV-infected children. Pediatr Infect Dis J 1997: 16: 216-221.
24. Galimberti R, Kowalczuk A, Hidalgo Parra I, Gonzalez Ramos M, Flores V. Cutaneous aspergillosis: a report of six cases. Br J Dermatol 1998: 139: 522-526.
25. Sanchez MR, Ponge-Wilson I, Moy JA, Rosenthal S. Zygomycosis and HIV infection. J Am Acad Dermatol 1994: 30: 904-908.
26. Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998: 26: 601-605.
27. Husain S, Alexander B, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003: 37: 221-229.
28. Jimenez C, Lumbreras C, Aguado JM et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation 2002: 73: 476-480.
29. Yehia M, Thomas M, Pilmore H, Van Der Merwe W, Dittmer I. Subcutaneous black fungus (phaeohyphomycosis) infection in renal transplant recipients: three cases. Transplantation 2004: 77: 140-142.
30. Merino E, Banuls J, Boix V, Franco A, Guijarro J, Portilla J, Betlloch I. Relapsing cutaneous altemariosis in a kidney transplant recipient cured with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 2003: 22: 51-53.
31. Baykal C, Kazancioǧlu N, Büyükbabani AV et al. Simultaneous cutaneous and ungual altemariosis in a renal transplant recipient. Br J Dermatol 2000: 143: 910-911.
32. Guarro J, Nucci M, Akiti T, Gené I. Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient. J Clin Microbiol 2000: 38: 3460-3462.
33. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002: 35: 909-920.
34. Bodey GP, Boktour M, Mays S et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol 2002: 47: 659-666.
35. Castro LG. Cutaneous Paecilomyces lilacinus infection. J Am Acad Dermatol 1998: 39: 516-517.
36. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001: 7: 375-381.
37. Pappas O, Patel R, Hadley S et al. Cryptococcosis in transplant recipients: an analysis of 102 subjects. Abstract #686, 42nd Infectious Disease Meeting, Boston 2004.
38. Dimino-Emme L, Gurevitch AW. Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 1995: 32 (5): 844-850.
39. Dromer F, Mathoulin S, Dupont B, Letenneur L, Ronin O. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. Clin Infect Dis 1996: 23: 91-96.
40. Hajjeh RA, Pappas PG, Henderson H et al. Multicenter case control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 2001: 32: 1215.
41. Miller HE, Keddie FM, Johnstone HG et al. Histoplasmosis: cutaneous and mucomembranous lesions, mycologic and pathologic observations. Arch Dermatol Syphilol 1947: 56: 715.
42. Cohen PR, Bank DE, Silvers DN et al. Cutaneous lesions of disseminated histoplasmosis in human immunodeficiency virus-infected patients. J Am Acad Dermatol 1990: 23: 422.
43. Eidbo J, Sanchez RL, Tschen JA et al. Cutaneous manifestations of histoplasmosis in the acquired immune deficiency syndrome. Am J Surg Pathol 1993: 17: 110.
44. Body B. Cutaneous manifestations of systemic mycoses. Dermatol Clin 1996: 14: 125-135.
45. Pappagianis D. Coccidioidomycosis. Semin Dermatol 1993: 12: 301-309.
46. Pappas P. Blastomycosis in the immunocompromised patient. Semin Respir Infect 1997: 12: 243-251.
47. Morris-Jones R. Sporotrichosis. Clin Exp Dermatol 2002: 27: 427-431.
48. Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am 2003: 17: 59-85.
49. Al-Tawfiq JA, Woods KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis 1998: 26: 1403-1406.
50. Bolao F, Podzamczer D, Ventin M, Gudiol F. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur J Clin Microbiol Infect Dis 1994: 13: 609-612.
51. Donabedian RM, O'Donnell E, Olszewski C, MacArthur RD, Budd N. Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn Microbiol Infect Dis 1994: 18: 111-115.
52. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996: 23: 125-130.
53. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994: 344: 110-113.
54. Ungpakom R. Cutaneous manifestations of Penicillium marneffei infection. Curr Opin Infect Dis 2000: 13: 129-134.
55. Cooper CR Jr, McGinnis MR. Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Arch Pathol Lab Med 1997: 121: 798-804.
56. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histology. Am J Clin Pathol 1998: 109: 45-54.
57. Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002: 49 (Sl): 11-19.
58. Gallagher JC, MacDougall C, Dodds Ashley ES, Perfect JR. Recent advances in antifungal phannacotherapy for invasive fungal infections. Expert Rev Anti Infect Ther 2004: 2: 253-258.
59. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004: 350: 950-952.
60. Mussini C, Pezzotti P, Mire J et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004: 38: 565-571.
61. Aberg J, Price R, Heeren D, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002: 185: 1179-1182.
62. Goldman M, Zackin R, Fichtenbaurn C et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004: 38: 1485-1489.
63. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002: 347: 408-415.
64. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. Clin Infect Dis 2000: 30: 684-687.